Quaggin Susan E, a director at AbbVie Inc., recently reported acquiring 59 stock equivalent units on September 30, 2026. This acquisition increases her total holdings to 918 units. Such transactions are significant as they reflect the confidence of company insiders in the firm’s future performance.
AbbVie Inc., a prominent player in the pharmaceutical preparations sector, is known for its innovative drug development. The company is incorporated in Delaware and has its fiscal year ending on December 31. AbbVie operates from North Chicago, Illinois, where it continues to develop and market a range of pharmaceutical products.
According to the SEC filing (accession number 0001997505-26-000010), the transaction was coded as an acquisition. The stock equivalent units were acquired at a conversion price of $261.59 per unit. The filing notes that these units are credited to an unfunded book account in the director's name and will earn returns similar to those of AbbVie stock.
This acquisition may impact shareholders and the broader market perception of AbbVie. Insider purchases can often signal confidence in a company’s prospects, potentially influencing investor sentiment positively.
The filing does not say what happens next.
Details of the Transaction
The SEC filing specifies that the stock equivalent units acquired by Susan E. Quaggin were part of a director fee arrangement. These units are credited to an unfunded book account in her name, which will distribute returns over a period equal to her years of service on the board, typically starting at age 65 or upon retirement from the board.
Additionally, the filing notes that the stock equivalent units earn returns that mirror those of AbbVie stock, indicating a direct link between her compensation and the company's performance.
Company Information
AbbVie Inc. is identified under the Central Index Key (CIK) number 0001551152 and operates under the trading symbol ABBV. The company is classified under the Standard Industrial Classification (SIC) code for pharmaceutical preparations, specifically 2834, which encompasses a wide range of pharmaceutical products and innovations.
"Director fees credited to an unfunded book account in the director's name are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board."
Notably, the filing does not provide further details on any future plans or expectations from AbbVie Inc., nor does it discuss the broader implications of this transaction on the company's stock performance or market strategy.